Link Between Fasting Plasma Glucagon Levels and Osteopenia/Osteoporosis

Overview

This study investigates the relationship between fasting plasma glucagon levels and the risk of osteopenia and osteoporosis in Chinese individuals with type 2 diabetes (T2DM). Elevated glucagon levels may serve as a metabolic indicator of skeletal fragility in this population, highlighting the need for further research in this area.

Background

Type 2 diabetes mellitus is associated with various complications, including significant impacts on bone health, with osteoporosis prevalence reaching 35.6% in affected individuals in mainland China. The relationship between glucagon levels and bone metabolism is not well understood, yet glucagon may reflect systemic derangements that contribute to bone fragility. Understanding this link is crucial for improving risk stratification and early identification of patients at risk for bone mass abnormalities.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• Fasting glucagon levels are elevated in patients with T2DM compared to healthy individuals.
• Hyperglucagonemia in T2DM may be due to α-cell dysfunction and chronic inflammation.
• There is a positive association between plasma glucagon levels and serum bone turnover markers in T2DM patients.
• Osteopenia and osteoporosis are significant concerns in T2DM, with multifactorial causes including oxidative stress and insulin resistance.
• Clinical evidence linking glucagon levels to osteopenia/osteoporosis remains limited and inconsistent.

Clinical Implications

Healthcare professionals should consider monitoring fasting plasma glucagon levels in patients with T2DM as part of a comprehensive assessment of bone health. Recognizing the potential link between glucagon and bone metabolism may aid in the early identification of patients at risk for osteopenia and osteoporosis.

Conclusion

The study underscores the importance of understanding the metabolic factors influencing bone health in T2DM. Further research is needed to clarify the role of glucagon in bone metabolism and its implications for patient management.

Related Resources & Content

1. The Journal of Clinical Endocrinology & Metabolism, 2025 -- The Individual and Synergistic Impact of GIP, GLP-1, and GLP-2 on Bone Turnover Biomarkers in Individuals with Type 2 Diabetes
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
3. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Influence of Osteocalcin on Insulin Sensitivity, Secretion, and β-cell Function in Mexican American Populations
4. The American Diabetes Association Releases Standards of Care in Diabetes—2025 | American Diabetes Association
5. Association between type 2 diabetes and site‐specific fracture risk: A systematic review and meta‐analysis of cohort studies including over 13 million participants - PMC
6. The Journal of Clinical Endocrinology & Metabolism — Bone Microstructure in Elderly Men with Type 2 Diabetes: Significance of Bone Dimensions
7. Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo
8. The American Diabetes Association Releases Standards of Care in Diabetes—2025 | American Diabetes Association
9. Association between type 2 diabetes and site‐specific fracture risk: A systematic review and meta‐analysis of cohort studies including over 13 million participants - PMC